The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The price of Travere Therapeutics Inc (NASDAQ: TVTX) closed at $16.70 in the last session, up 5.16% from day before closing price of $15.88. In other words, the price has increased by $5.16 from its previous closing price. On the day, 1.52 million shares were traded.
Ratios:
We take a closer look at TVTX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 2.04 and its Current Ratio is at 2.08. In the meantime, Its Debt-to-Equity ratio is 6.80 whereas as Long-Term Debt/Eq ratio is at 5.54.
On October 21, 2024, Wells Fargo Upgraded its rating to Overweight which previously was Equal Weight and also upped its target price recommendation from $9 to $27.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Apr 11 ’25 when Cline Christopher R. sold 48 shares for $13.14 per share. The transaction valued at 631 led to the insider holds 89,990 shares of the business.
Christopher Cline bought 48 shares of TVTX for $631 on Apr 11 ’25. On Feb 12 ’25, another insider, ROTE WILLIAM E., who serves as the SENIOR VICE PRESIDENT, R&D of the company, sold 5,200 shares for $23.53 each. As a result, the insider received 122,356 and left with 98,519 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 6.36 while its Price-to-Book (P/B) ratio in mrq is 24.72.
Stock Price History:
Over the past 52 weeks, TVTX has reached a high of $25.29, while it has fallen to a 52-week low of $5.12. The 50-Day Moving Average of the stock is -12.06%, while the 200-Day Moving Average is calculated to be 3.41%.
Shares Statistics:
A total of 87.45M shares are outstanding, with a floating share count of 87.44M. Insiders hold about 1.50% of the company’s shares, while institutions hold 109.06% stake in the company.
